UNSPSC 51283005: Clindamycin palmitate hydrochloride

This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VN9A8JM7M7, chemically known as methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside 2-palmitate monohydrochloride but more generally known as clindamycin palmitate hydrochloride, which bears US NIH Compound Identifier 33030.

UNSPSC 51283005 Clindamycin palmitate hydrochloride is a Commodity code that nominally addresses a single antibiotic pharmaceutical product, yet recent state and local procurement activity under this code shows minimal direct relevance to clindamycin itself. Instead, the opportunities tagged to this code span broader pharmaceutical procurement — from emergency medical supplies and naloxone distribution to multi-state generic pharmaceutical contracting and direct-to-manufacturer prescription programs. The actual buying activity reflects state and local health agencies, fire departments, and cooperative purchasing alliances sourcing medical consumables, OTC products, and emergency response pharmaceuticals through competitive bidding and RFP processes. The code's nominal specificity does not align with the scope of work being solicited; purchasers are acquiring portfolios of pharmaceutical and medical products rather than clindamycin palmitate hydrochloride in particular.

Issuing bodies include county health departments, municipal fire departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Seminole County, Florida (IFB60459723LAS, posted June 30, 2026, response due July 26, 2023) solicited naloxone and drug deactivation systems through competitive sealed bidding with quarterly deliveries to a community health facility. The City of Tampa (26P00145, posted March 25, 2026, response due March 13, 2026) bid 169 line items of medical and first aid supplies for its Fire Department Rescue Division under a sheltered Small Local Business Enterprise set-aside with an estimated contract value of $700,000. The Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, posted January 20, 2026, response due March 26, 2026) issued an RFP for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, DSCSA, and authorized-wholesaler networks. The Texas Health and Human Services Commission (HHS0017013, posted April 3, 2026, response due April 3, 2026) issued an RFI to explore direct-to-manufacturer prescription contracting capabilities. Geographic activity appears concentrated in Florida, Minnesota, Oregon, and Texas, with cooperative purchasing extending multi-state reach. The code shows activity but does not reflect procurement focused on clindamycin palmitate hydrochloride as a discrete product line.